Serca – The Cardioprotection company
Changing the outcomes in heart attack treatment
Our mission is to improve the quality of life of patients with myocardial infarction (MI) and heart failure by providing novel cardioprotective treatments
Myocardial Infartion (MI), or heart attack, occurs when blood flow decreases or stops to a part of the heart causing damage (infarction) to the heart muscle.
Approximately 7 million people is affected by MI each year.Read more
Serca Pharmaceuticals is developing its lead drug candidate, a new chemical entity (NCE) shown to selectively affect the contractile force of the heart through modulation of he SERCA2 calcium pump.Read more